WO1990006772A1 - Nouveaux anticorps monoclonaux de carcinomes humains - Google Patents

Nouveaux anticorps monoclonaux de carcinomes humains Download PDF

Info

Publication number
WO1990006772A1
WO1990006772A1 PCT/US1989/005802 US8905802W WO9006772A1 WO 1990006772 A1 WO1990006772 A1 WO 1990006772A1 US 8905802 W US8905802 W US 8905802W WO 9006772 A1 WO9006772 A1 WO 9006772A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
monoclonal antibody
cells
human
carcinoma
Prior art date
Application number
PCT/US1989/005802
Other languages
English (en)
Inventor
Ingegerd Hellstrom
Karl Erik Hellstrom
Original Assignee
Oncogen Limited Partnership
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen Limited Partnership filed Critical Oncogen Limited Partnership
Priority to JP90501917A priority Critical patent/JPH04502702A/ja
Publication of WO1990006772A1 publication Critical patent/WO1990006772A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Definitions

  • the present invention relates to a novel monoclonal antibody reactive with human carcinoma cells. More
  • the antibody of the invention is a monoclonal antibody that reacts with a glycolipid cell membrane antigen found on the surface of human carcinomas, such as carcinomas of the colon, breast, ovary, and lung.
  • the antibody is highly specific for carcinoma cells, showing a low degree cf reactivity with certain normal human cells and no detectable reactivity with other types of tumors, such as lymphomas, sarcomas or melanomas.
  • the antibody has the added advantage of internalizing within the carcinoma cells to which it binds.
  • the antibody of this invention is, therefore, particularly useful for therapeutic applications, for example, as the antibody component of antibody-drug or antibody-toxin conjugates where internalization of the conjugate is desired.
  • the antibody is also useful in diagnostic methods, such as the detection of malignant carcinomas.
  • monoclonal antibodies are principally reactive with specific types of human carcinomas derived from specific organs of the body, e.g., lung, breast, ovarian, colon or other gastrointestinal carcinomas, and can bind to carcinoma-associated antigens that are either glycoprotein or glycolipid in nature [see, e.g., L. M. Fink et al., "Monoclonal Antibodies as Diagnostic Reagents for the Identification and Characterization of Human Tumor Antigens", Prog. Clin. Pathol., 9, pp. 121-133 (1984)].
  • monoclonal antibodies that bind to glycoprotein antigens on specific types of carcinomas include those described in United States Patent 4,737,579 (monoclonal antibodies to non-small cell lung carcinomas), United States
  • Patent 4,753,894 (monoclonal antibodies to human breast cancer), United States Patent 4,579,827 (monoclonal
  • glycoprotein antigen of greater than 1,000 kd molecular weight that is selectively expressed on a number of
  • B72.3 has been shown to react with 84% of breast carcinomas, 94% of colon carcinomas, 100% of ovarian carcinomas, and 96% of non-small-cell lung carcinomas [see W. W. Johnston, "Applications of Monoclonal
  • KC-4 recognizes an approximately 400-500 kd protein antigen expressed on a number of carcinomas, such as colon,
  • KC-4 antibodies internalize within the carcinoma cells with which they react. Monoclonal antibodies reactive with glycolipid antigens that are believed to be associated with certain tumor cells have also been disclosed. For example, W. W. Young et al., "Production of Monoclonal Antibodies Specific for Two
  • Gangliotriaosylceramide (Asialo GM 2 ), A Glycosphingolipid Marker for Cell Lines Derived from Patients with Hodgkin's Disease", J. Immunol., 131 (No. 3), pp. 1591-1594 (1983), and United States Patent 4,507,391 (monoclonal antibody to human melanoma).
  • monoclonal antibodies reactive with glycolipid antigens found on specific types of carcinoma cells include those described by S. T. Rosen et al.,
  • L6 monoclonal antibody that recognizes a carbohydrate antigen expressed on the surface of human non-small cell lung carcinomas, breast carcinomas, and colon carcinomas.
  • the antigen with which the L6 antibody reacts iri one that does not internalize within the carcinoma cell.
  • monoclonal antibodies exhibiting a reactivity to carcinoma cells are greatly needed. This is so because of the antigenic heterogeneity of many carcinoma tumors which often necessitates, in diagnosis or therapy, the use of a number of different monoclonal antibodies to the same tumor mass. Furthermore, monoclonal antibodies that display a high degree of selectivity to a wide range of carcinoma tissues are not common, and any such antibody would clearly be advantageous.
  • internalizing antibodies i.e., antibodies that are capable of being internalized within the tumor cell to which they bind.
  • This type of antibody finds use in tumor therapy methods involving antibody-drug or antibody-toxin conjugates wherein a therapeutic antitumor agent is linked to an antibody for delivery to the site of a tumor, where the antibody binds to the tumor-associated antigen with which it is reactive and “delivers" the antitumor agent to the tumor site [see, e.g., M. J. Embleton et al., "Antibody Targeting of Anti-Cancer Agents", in Monoclonal Antibodies for Cancer Detection and Therapy, pp.
  • An example of an internalizing antibody is the
  • glycoprotein is also expressed on normal tissues, the use of an anti-transferrin-receptor antibody in a antibody-drug or antibody-toxin conjugate may have significant toxic effects on normal cells.
  • the utility of this antibody for selective killing or inhibition of tumor cells is therefore
  • the present invention provides such an internalizing antibody that is highly selective for a range of human carcinomas.
  • the novel antibody of the invention illustrated by BR64, is a monoclonal antibody that binds to a glycolipid cell membrane antigen found on the surface of human carcinoma cells.
  • the antibody is highly specific for carcinoma cells, such as those derived from breast, lung, colon, and ovarian carcinomas, showing only a low degree of reactivity with certain normal human cells and no detectable reactivity with other types of tumors, such as lymphomas, sarcomas or melanomas.
  • the antibody of the invention internalizes within the carcinoma cells to which it binds and thus is of
  • the antibody is also useful in in vitro or in vivo diagnostic methods for the detection of carcinoma cells.
  • Figure 1 depicts the percent inhibition of thymidine incorporation into the DNA of H2707 lung carcinoma cells treated with a BR64-RA immunotoxin at varying
  • L6-RA is a non-internalizing negative control. This figure demonstrates internalization of the immunotoxin.
  • Figure 2 depicts the percent inhibition of thymidine incorporation into the DNA of H3396 breast carcinoma cells treated with a BR64-RA immunotoxin at varying
  • P1.17-RA is a non-internalizing negative control. This figure demonstrates internalization of the immunotoxin.
  • Figure 3 depicts the percent inhibition of thymidine incorporation into the DNA of C colon carcinoma cells treated with a BR64-RA immunotoxin at varying
  • P1.17-RA was used as a negative control. This figure demonstrates internalization of the immunotoxin.
  • Figure 4 depicts the percent inhibition of thymidine incorporation into the DNA of RCA colon carcinoma cells treated with a BR64-RA immunotoxin at varying
  • P1.17-RA was used as a negative control. This figure demonstrates internalization of the immunotoxin.
  • Figure 5 depicts the percent inhibition of thymidine incorporation into the DNA of JiJoye cells treated with a BR64-RA immunotoxin at varying concentrations.
  • L6-RA is a non-internalizing negative control. No internalization of the immunotoxin occurred.
  • Figure 6 depicts the percent inhibition of thymidine incorporation into the DNA of normal human fibroblast cells treated with a BR64-RA immunotoxin at varying
  • P1.17-RA was used as a negative control.
  • Figure 7 depicts the uptake of 125 I-labeled BR64 antibody by breast carcinoma cells within one hour after a pulse-chase experiment. Measurements were taken of labeled antibody in the cell media: - ⁇ -, on the cell surface:
  • Figure 8 depicts the uptake of 125 I-labeled BR64 antibody by breast carcinoma cells within six hours after a pulse-chase experiment. Measurements were taken of labeled antibody in the cell media: - ⁇ -, on the cell surface:
  • Figure 9 depicts the percent inhibition of thymidine incorporation into the DNA of H3396 breast carcinoma cells treated with a BR64-adriamycin conjugate. A significant cytotoxic effect was demonstrated.
  • Figure 10 depicts the binding of the BR64 antibody of the invention to various cultured carcinoma cell lines.
  • Peripheral blood leukocytes were used as a negative control.
  • a ratio between the brightness (LFE) of cells stained by BR64 vs. a control antibody was determined by
  • Figure 11 is a bar graph depicting the results of an ELISA assay to detect the binding of the BR64 antibody to known glycolipid antigens.
  • the present invention relates to a novel monoclonal antibody that is highly specific for human carcinoma cells. More particularly, the antibody reacts with a range of carcinomas, such as breast, lung, ovary, and colon
  • tumors such as melanomas, sarcomas or lymphomas.
  • glycolipid antigen [see, e.g., J. L. Magnani, "Mouse And Rat Monoclonal Antibodies Directed Against Carbohydrates", in Methods Enzvmol., 138, pp. 484-491 (1987)].
  • This data indicates that the antibody of this invention recognizes a complex epitope of a novel pan-carcinomic glycolipid antigen, a portion of that epitope comprising an Le y carbohydrate chain.
  • an antitumor agent e.g., drug or toxin
  • the monoclonal antibody of the invention can be any monoclonal antibody of the invention.
  • an immunogen e.g., cells or cellular extracts carrying the antigen or purified antigen
  • an animal e.g., a mouse
  • a desired immune response i.e., antibodies
  • lymphocytes are obtained from the animal either from the spleen, lymph nodes or peripheral blood.
  • the lymphocytes are obtained from the spleen.
  • the splenic lymphocytes are then fused with a myeloma cell line, usually in the presence of a fusing agent such as polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • Any of a number of myeloma cell lines may be used as a fusion partner according to standard techniques; for example, the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or
  • Sp2/0-Ag14 myeloma lines are available from the American Type Culture Collection, Rockville,
  • hybridomas are then grown in a selective medium, such as HAT medium, in which unfused parental myeloma or lymphocyte cells eventually die. Only the hybridoma cells survive and can be grown under limiting conditions to obtain isolated clones. The supernatants of the hybridomas are screened for the presence of antibody of that desired specificity, e.g., by immunoassay techniques using the antigen that had been used for immunization. Positive clones can then be subcloned under limiting dilution conditions and the monoclonal antibody produced can be isolated. Hybridomas produced according to these methods can be propagated in vitro or in vivo (in ascites fluid) using techniques known in the art [see, generally, L. M. Fink et al., supra, p. 123, Fig. 6-1]. Commonly used methods for purifying monoclonal antibodies include ammonium sulfate
  • an antibody of this invention designated BR64, was produced via the hybridoma techniques described herein below using a breast cancer cell line 3396 as the immunogen.
  • the BR64 hybridoma, prepared as described herein below and producing the BR64 antibody, was deposited on November 3, 1988, with the
  • the BR64 antibody is a murine antibody of the IgG1 subclass.
  • the antibody displays a strong reactivity with a wide range of human carcinoma cells of different organ types, for example, tumors of the breast, lung, colon, stomach,
  • the BR64 antibody shows no detectable binding to other types of tumor cells, such as the T cell lymphoma cell lines, CEM and
  • MOLT-4 the B cell lymphoma cell line P3HR-1, melanoma cells or sarcoma cells.
  • the antibody of this invention does not display any immunohistologically detectable binding to most normal human tissues, such as fibroblast, endothelial or epithelial cells from most of the major organs of the body, e.g., kidney, spleen, liver, skin, lung, breast, colon, brain, thyroid, lymph nodes or ovary.
  • the antibody react with peripheral blood leukocytes or bone marrow stem cells.
  • the antibody does react with certain normal tissues as follows: epithelial cells of the stomach and oesophagus, acinar cells of the pancreas, and occasional cells of the tonsils and testis.
  • the BR64 antibody appeared to react with cells from salivary glands and Paneth cells in the duodenum.
  • the antibody stained capillaries from three out of six samples of normal heart; however, no such staining was seen with three hearts in studies carried out in the laboratories of the present inventors.
  • the present antibody is superior to most other known antitumor antibodies in its high degree of specificity for tumor cells as compared to normal cells tsee, e.g., K. E. Hellstrom et al.,
  • the present invention encompasses the BR64 antibody described above and any fragments thereof containing the active antigen-binding region of the antibody, such as Fab, F(ab') 2 and Fv
  • fragments can be produced from the BR64 antibody using techniques well established in the art [see, e.g., J. Rousseaux et al., "Optimal Conditions for the
  • antibodies that are capable of binding to the same antigenic determinant or epitope as the BR64 antibody and competing with the BR64 antibody for binding at that site include antibodies having the same antigenic specificity as the BR64 antibody but differing in species origin, isotype, binding affinity or biological functions (e.g.,
  • cytotoxicity For example, class, isotype and other variants of the antibody of the invention having the
  • antigen-binding region of the BR64 antibody may be any antigen-binding region of the BR64 antibody.
  • invention having the antigen-binding region of the BR64 antibody may be obtained by selection of naturally-occurring class-switch mutants as described by G. Spira et al., "The Identification of Monoclonal Class Switch Variants by Sib Selection and an ELISA Assay", J. Immunol. Methods, 74, pp. 307-315 (1984). Such variants also fall within the definition of the antibody of this invention.
  • BR64.60 an IgG2a variant of BR64, hereinafter referred to as BR64.60, was obtained.
  • the variable region of BR64.60 is the same as that of original BR64 and thus the two antibodies have the same specificity.
  • BR64 sometimes exhibits a weak ADCC
  • this IgG2a variant possesses significant ADCC, as well as CDC
  • the BR64.60 hybridoma that produces the IgG2a variant of BR64 was deposited on November 7, 1989, with the ATCC and has there been
  • the antibody of this invention can be used to isolate and characterize the a ⁇ tigen to which it binds.
  • BR64 or BR64.60 can be used as a probe to identify and
  • the BR64 antibody was tested for its reactivity to a variety of immobilized glycolipids of known carbohydrate structure in an ELISA assay and was shown to bind to an Le y [Fuc ⁇ 1-2Ga1ß1-4(Fuc ⁇ 1-3)GlcNAc] antigen, as well as an H2 [Fuc ⁇ l-2Ga1ß1-4GlcNAc] glycolipid. It should be noted that there are other monoclonal antibodies in the art known to react with Le y antigens; yet, none of those antibodies have been described as exhibiting the tumor specificity and ability to internalize displayed by the antibody of this invention.
  • the present antibody recognizes a complex epitope on a novel pan-carcinomic antigen, a portion of that epitope comprising an Le y antigen.
  • the present inventors have provided the means with which to obtain this novel antigen.
  • the present invention therefore encompasses antibodies that bind to any antigenic determinant or epitope on this novel antigen, including epitopes other than that with which BR64 reacts.
  • anti-idiotypic antibodies of the BR64 antibody of the invention are also included within the scope of the invention. These anti-idiotypic antibodies can be produced using the BR64 antibody as immunogen and are useful for diagnostic purposes in detecting humoral response to tumors and in therapeutic applications, e.g., in a vaccine, to induce an anti-tumor response in patients [see, e.g.,
  • the monoclonal antibody of the invention is also useful for diagnostic applications, both in vitro and in vivo, for the detection of human carcinomas that possess the antigen for which the antibody is specific.
  • diagnostic methods include immunohistological detection of tumor cells (e.g., on human tissue, cells or excised tumor specimens) or serologic detection of tumor-associated antigens (e.g., in blood samples or other biological fluids).
  • Immunohistochemical techniques involve contacting a biological specimen, such as a tissue specimen, with the antibody of the invention and then detecting the presence on the specimen of the antibody complexed to its antigen. The formation of such antibody-antigen complexes with the specimen indicates the presence of carcinoma cells in the tissue. Detection of the antibody on the specimen can be accomplished using techniques known in the art such as immunoenzymatic techniques, e.g., the immunoperoxidase staining technique or the avidin-biotin (ABC) technique, or immunofluorescence techniques [see, e.g., D. R. Ciocca et al., "Immunohistochemical Techniques Using Monoclonal
  • Serologic diagnostic techniques involve the detection and quantitation of tumor-associated antigens that have been secreted or "shed” into the serum or other biological fluids of patients thought to be suffering from carcinoma. Such antigens can be detected in the body fluids using techniques known in the art such as radioimmunoassays (RIA) or
  • ELISA enzyme-linked immunosorbent assays
  • an antibody reactive with the "shed” antigen is used to detect the presence of the antigen in a fluid sample
  • a fluid sample see, e.g., M. Uotila et al., "Two-Site Sandwich ELISA with MonoclonalAntibodies to Human AFP", J. Immunol. Methods, 42, p. 11 (1981) and W. H. Allum et al., supra at pp. 48-51].
  • These assays, using the BR64 antibody disclosed herein can therefore be used for the detection in biological fluids of the glycolipid antigen with which the BR64 antibody reacts and thus the detection of human carcinoma in patients.
  • antigen-antibody reactions include, but are not limited to, standard RIA techniques, both liquid and solid phase, as well as ELISA assays procedures,
  • the invention also encompasses diagnostic kits for carrying out the assays described above.
  • the diagnostic kit comprises the BR64 (or BR64.60)
  • the diagnostic kit may further comprise, where necessary, other components of the signal-producing system, including agents for reducing background interference, control reagents or an apparatus or container for conducting the test.
  • the diagnostic kit comprises a conjugate of the BR64 (or BR64.60) monoclonal antibody of the invention and a label capable of producing a detectable signal.
  • Ancillary agents as mentioned above, may also be present.
  • the antibody of the invention is also useful for in vivo diagnostic applications for the detection of human carcinomas.
  • One such approach involves the detection of tumors in vivo by tumor imaging techniques.
  • the antibody or fragments thereof e.g., Fab or F(ab') 2
  • an appropriate imaging reagent that produces a detectable signal.
  • imaging reagents include, but are not limited to, radiolabels such as 131 I, 111 In, 123 I, 99m Tc, 32 P, 125 I, 3 H, and 14 C, fluorescent labels such as fluorescein and
  • the antibody can be labeled with such reagents using techniques known in the art. For example, see Wensel and Meares, Radioimmunoimaging and Radioimmunotherapy, Esevier, New York (1983), for techniques relating to the radiolabeling of antibodies [see also, D. Colcher et al., "Use of Monoclonal Antibodies as Radiopharmaceuticals for the Localization of Human Carcinoma Xenografts in Athymic Mice", Meth. Enzymol., 121, pp. 802-816 (1986)].
  • the antibody is administered to the patient, localizes to the tumor bearing the antigen with which the antibody reacts, and is detected or "imaged" in vivo using known techniques such as
  • radionuclear scanning using, e.g., a gamma camera or
  • the antibody is administered to the patient in a pharmaceutically acceptable carrier, such as water, saline, Ringer's solution, Hank's solution or nonaqueous carriers such as fixed oils.
  • a pharmaceutically acceptable carrier such as water, saline, Ringer's solution, Hank's solution or nonaqueous carriers such as fixed oils.
  • the carrier may also contain substances that enhance isotonicity and chemical stability of the antibody such as buffers or preservatives.
  • the antibody formulation is administered, for example, intravenously at a dosage sufficient to provide enough gamma emission to allow visualization of the tumor target site.
  • the BR64 antibody of the invention has a number of in vivo therapeutic applications.
  • the antibody can be used in conjunction with an appropriate therapeutic agent to treat human carcinoma.
  • the antibody can be conjugated or linked to a therapeutic drug or toxin for delivery of the therapeutic agent to the site of the
  • Monoclonal Antibodies '84 Biological and Clinical
  • the BR64 antibody of the invention is particularly suited for use in a therapeutic conjugate because it is readily internalized within the carcinoma cells to which it binds and so can deliver the therapeutic agent to intracellular sites of action.
  • the antibody can be coupled to
  • a radioisotope such as 131 I
  • the BR64 can be conjugated to a second antibody to form an antibody heteroconjugate for the treatment of tumor cells as
  • Still other therapeutic applications for the BR64 antibody of the invention include its conjugation or
  • BR64 antibody therapeutic use for the BR64 antibody involves its use, either in the presence of complement or as part of an antibody-drug or antibody-toxin conjugate, to remove tumor cells from the bone marrow of cancer patients.
  • autologous bone marrow may be purged ex vivo by treatment with the antibody and the marrow infused back into the patient [see, e.g., N. K. C. Ramsay et al., "Bone Marrow Purging Using Monoclonal Antibodies", J. Clin.
  • chimeric or other recombinant BR64 antibodies of the invention may be used therapeutically.
  • a fusion protein for example, a fusion protein
  • a second protein having anti-tumor activity comprising at least the antigen-binding region of the BR64 antibody joined to at least a functionally active portion of a second protein having anti-tumor activity, e.g., a
  • lymphokine or oncostatin may be used to treat human
  • a chimeric BR64 antibody wherein the antigen-binding region of BR64 is joined to a human Fc region, e.g., IgG1, may be used to promote
  • variants of the BR64 antibody such as class-switch variants, may be used therapeutically.
  • the IgG2a variant, BR64.60, disclosed herein can promote ADCC and CDC by virtue of its particular subclass.
  • anti-idiotypic antibodies of the BR64 antibody may be used therapeutically in active tumor immunization and tumor therapy [see, e.g., K. E. Hellstrom et al.,
  • the present invention encompasses pharmaceutical compositions, combinations, and methods for treating human carcinomas.
  • the invention includes pharmaceutical compositions for use in the treatment of human carcinomas comprising a
  • compositions may contain the BR64 antibody, either unmodified, conjugated to a therapeutic agent (e.g., drug, toxin, enzyme or second antibody) or in a recombinant (e.g., chimeric or bispecific BR64) or variant form.
  • a therapeutic agent e.g., drug, toxin, enzyme or second antibody
  • a recombinant e.g., chimeric or bispecific BR64
  • variant form e.g., chimeric or bispecific BR64
  • carcinomas e.g., an antibody cocktail.
  • the antibody compositions of the invention can be administered using conventional modes of administration, including, but not limited to, intravenous, intraperitoneal, oral, intralymphatic or administration directly into the tumor. Intravenous administration is preferred.
  • the antibody compositions of the invention may be in a variety of dosage forms which include, but are not limited to, liquid solutions or suspensions, tablets, pills,
  • the antibody compositions also preferably include conventional pharmaceutically acceptable carriers and adjuvants known in the art such as human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate.
  • an effective dose of the antibody compositions of this invention may be in the range of from about 1 to about 2,000 mg/m 2 .
  • the BR64 monoclonal antibody of the invention was produced using hybridoma fusion techniques as described previously by M. Yeh et al., Proc. Natl. Acad. Sci. USA, (1979), supra, and M. Yeh et al., Int. J. Cancer (1982), supra. Briefly, a three month-old BALB/c mouse was
  • the mouse received injections on four occasions: on the first three occasions, the mouse received 1 intraperitoneal injection and 1 subcutaneous injection split between 4 sites on the mouse. On the fourth occasion, the mouse was given only 1 intraperitoneal injection. The total number of cells injected on each occasion was approximately 10 7 cells.
  • spleen was removed and spleen cells were suspended in NS-1 culture medium. The spleen cells were then fused with NS-1 mouse myeloma cells in the presence of polyethylene glycol (PEG) and the cell suspension grown in microtiter wells in
  • the supernatants from these hybridoma cultures were then screened for direct binding activity on the breast cancer cell line, 3396, and a fibroblast cell line, using an
  • the antibody will bind to the immobilized antigen and is detected by addition of an anti-immunoglobulin antibody-enzyme conjuage and a substrate for the enzyme which leads to a measurable change in optical density.
  • breast cancer cells or control In the present studies, breast cancer cells or control
  • fibroblast cells were dispensed into a 96-well tissue culture plate (Costar Cambridge, MA) and incubated overnight in a humid 37°C incubator (5% CO 2 ). The cells were then fixed with 100 ⁇ l of freshly prepared 1.0% glutaraldehyde to a final well concentration of 0.5% and incubated for 15 min at room temperature, followed by washing three times with 1 X PBS. The cells were next blocked for 30 min with 5% BSA in PBS and washed again three times with PBS. The supernatants from the hybridoma cultures were then added at 100 ⁇ l/well, the wells incubated for 1 h at room
  • this assay can be performed using intact cells or purified soluble antigen or cellular extracts as the immobilized antigen.
  • soluble antigen or cell extracts were used as antigen, the antigen was initially plated at 50 ⁇ l/well in PBS and the plates were incubated overnight at room temperature before beginning the assay.
  • intact cells they may be used fresh or after fixation. In either case, the cells were initially plated at 10 4 cells at 100 ⁇ l/well in culture medium and incubated overnight in a 37°C incubator (5% CO 2 ).
  • Hybridomas which produced antibodies binding to the breast cancer cell line and not to the fibroblast line were thus selected, cloned, expanded in vitro, and further tested for antibody specificity. Those hybridomas producing antibody reactive with human breast cancer were recloned, expanded, and injected into pristane-primed 3-month old BALB/c mice, where they grew as ascites tumors.
  • hybridoma cell line BR64 was obtained, cloned, and injected into mice to develop as an ascites tumor.
  • the BR64 hybridoma has been deposited with the ATCC Antibody secreted into the ascites was purified on protein A-Sepharose [see, e.g., P. L. By et al., Imrnunochemistry, 15, pp. 429-436 (1978)] or by gel filtration on Sephacryl S-300. Purified BR64 antibody was used for further characterization.
  • Dynatech Immunolon 96-well plates were coated with goat anti-mouse Ig antibodies at 1 ⁇ g/ml concentration, 50 ⁇ l/well in PBS and left covered overnight at 4°C. The plates were washed with PBS/Tween 20, 0.05%, and blocked with medium at 100 ⁇ l/well for 1 h at room temperature.
  • hybridoma were added and incubated at room temperature for 1 h. After washing with PBS containing 2% bovine serum albumin (BSA), plates were incubated at 37oC for 30 min with monospecific rabbit anti-mouse Ig isotype antibodies coupled to peroxidase (Zymed). After further washing, the plates were incubated with 1 mg/ml o-phenylenediamine and 0.03% H 2 O 2 in 0.1 M citrate buffer, pH 4.5. Optical density at 630 nm was determined on a Dynatec ELISA plate reader.
  • BSA bovine serum albumin
  • the BR64 monoclonal antibody is of the IgG1 isotype.
  • the target tissues for these tests were obtained at surgery and frozen within 4 h of removal using isopentane precooled in liquid nitrogen.
  • Tissues were then stored in liquid nitrogen or at -70°C until used. Frozen sections were prepared, air-dried, treated with acetone, and dried again [see H. J. Garrigues et al., supra]. Sections to be used for histologic
  • Immunochemicals, Inc. containing 2 mg/ml of specifically purified PAP was used at a dilution of 1/80.
  • the staining procedure consisted of treating serial sections with either specific antibody, i.e., BR64, or a control antibody for 2.5 h, incubating the sections for 30 min at room temperature with rabbit anti-mouse IgG diluted 1/50 and then exposing the sections to mouse PAP complexes diluted 1/80 for 30 min at room temperature. After each treatment with antibody, the slides were washed twice in PBS.
  • the immunohistochemical reaction was developed by adding freshly prepared 0.5% 3,3'-diaminobenzidine
  • Typical slides were photographed by using differential interference contrast optics (Zeiss-Nomarski). The degree of antibody staining was evaluated as 0 (no reactivity), + (a few weakly positive cells), ++ (at least one third of the cells positive), +++ (most cells positive), and ++++
  • Table I demonstrates the immunohistological staining of various tumor and normal tissue specimens using the BR64 monoclonal antibody. As the table clearly
  • the BR64 antibody reacts with a wide range of human carcinoma specimens, does not react with non-carcinoma tumors such as melanoma and sarcoma, and shows no reactivity with a large number of normal human tissues tested.
  • carcinoma cells are strongly staine by the BR64 antibody.
  • the antibody did show a weak binding to occasional cells in the testis and tonsils, and a reactivity with epithelial cells of the stomach and
  • Peripheral blood leukocytes 1 As Table II and Figure 10 demonstrate, the BR64 monoclonal antibody reacted with human breast, lung, and colon carcinoma cell lines but did not react with T or B lymphoma lines nor with normal peripheral blood leukocytes.
  • BR64 also did not react with bone marrow stem cells (data not shown). Scatchard analysis using radiolabeled antibody indicated that the BR64 antibody has an approximate
  • BR64 was conjugated to the ricin A chain toxin to form an immunotoxin, BR64-RA, whose
  • Conjugation of the antibody to the toxin was carried out as follows: Deglycosylated ricin-A chain (Inland Labs, Austin, TX) [see, also, D. C. Blakey et al., Cancer Res., 47, pp. 947-952 (1987)] was treated with dithiothreitol (5 mM) prior to gel filtration on G-25 Sephadex using PBS, pH 7.2 as eluant. This was added in a 2:1 molar ratio to the antibody in PBS, the antibody having been previously modified with N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) (Pierce, Rockford, IL) according to the procedure of J. M.
  • SPDP N-succinimidyl-3-(2-pyridyldithio) propionate
  • BR64-RA The internalization of BR64-RA by various carcinoma cell lines was then measured using a thymidine uptake inhibition assay.
  • the inhibition of 3 H-thymidine incorporation into the DNA of the carcinoma cells i.e., the inhibition of cell proliferation
  • the inhibition of cell proliferation is a measure of the cytotoxic effect of BR64-RA on the cells and thus a measure of the internalization of the immunotoxin within the cell.
  • Carcinoma cells were plated into a 96-well microtiter plate at 1 ⁇ 10 4 cells/well in 150 ⁇ l of IMDM medium with 10% fetal calf serum (FCS).
  • FCS fetal calf serum
  • the BR64-RA immunotoxin (50 ⁇ l) was then added in log 10 serial dilutions, starting at 10 ⁇ g/ml final concentration down to 0.01 ⁇ g/ml.
  • the reaction mixture was incubated for 6 h at 37oC in a 5% CO 2 incubator. At this point, 50 ⁇ l of 3 H-thymidme was added at 1
  • the assay plate was then frozen at -70°C for at least 1 h and thawed in a gel dryer for 15 min.
  • the cells were harvested onto glass fiber filters (Filter
  • FIGS 1-6 In each assay, a non-internalizing immunotoxin control, L6-RA or P1.17-RA, was run.
  • L6 is an antibody that reacts with carcinoma cells but does not internalize.
  • P1.17 is a non-internalizing IgG2a mouse myeloma protein that does not bind to any human cells and is available from the ATCC.
  • Figure 1 depicts the percent inhibition of thymidine incorporation by cells from the H2707 lung carcinoma cell line caused by internalization of BR64-RA. Similar results were obtained with the H3396 breast carcinoma cell line, C colon carcinoma cell line, and RCA colon carcinoma cell line
  • BR64 antibody was internalized by these carcinoma cells.
  • BR64-RA was not internalized by the JiJoye cell line, a human B lymphoma cell line or by normal human fibroblasts (see Figures 5 and 6). This study therefore demonstrated not only
  • a second internalization study measured the uptake of the BR64 monoclonal antibody by the breast carcinoma cell line 3396, using radiolabeled BR64.
  • the antibody was radiolabeled as follows: 20-40 ⁇ g of antibody was incubated with 1 mCi of Na 125I (Amersham) and
  • I-BR64 was approximately 5.4 X 10 cpm/ ⁇ g.
  • the antibody was diluted with an equal volume of 2% BSA in PBS and aliquots were frozen at -70°C [see, e.g., M. Yeh et al.,
  • I-BR64 was then used to measure internalization of the antibody as follows: Tumor cells from the breast cancer line 3396 (2 ⁇ 10 6 /35 mm dish) were cultured overnight in IMDM media containing 15% fetal calf serum (FCS). The cells were pre-cooled with cold (4oC) PBS for 5 min and then incubated with the 125 I-BR64 (10 cpm) at 4°C for 30 min on a rocker platform. Unbound antibody was removed by
  • the cells were transferred to a 37oC incubator and cultured for certain designated “chase” times. At the end of each chase period, the culture media was collected and counted in a gamma counter. This was designated the "media” fraction and represented monoclonal antibody released by the cells.
  • BR64 monoclonal antibody associated with the cell surface decreased rapidly with a reciprocal increase in the
  • BR64 is rapidly internalized within the carcinoma cells. Over time, the majority of the antibody is released into the culture media; however, there is a significant proportion associate with the intracellular compartment even after 6 hours. As discussed earlier, the ability of the BR64 antibody of this invention to be internalized within the carcinoma cells with which it reacts makes the antibody particularly useful for therapeutic applications for the treatment of human
  • the present example further illustrates the therapeutic potential of the BR64 antibody in the form of an
  • a BR64-adriamycin conjugate showed a significant cytotoxic effect on carcinoma cells in vitro.
  • the BR64-adriamycin (ADR) conjugate was constructed as follows: ADR was derivatized with cis-aconitic anhydride using a method previously reported for the derivatization of daunomycin [see W. C. Shen et al., Biochim. Biophys. Res. Commun., 102, pp. 1048-1054 (1981)]. The lyophilized product was dissolved in PBS (2.4 mg/ml) and activated with 2 eq. of 1-ethyl-3-(3-dimethylamino propyl) carbodiimide (EDC) (Pierce, Rockford, IL). After 10 min at room
  • the drug derivative was added to the BR64 antibody (5-10 mg/ml in PBS) in a 15:1 mole ratio and the reaction was allowed to proceed for 2-4 h.
  • Gel filtration on G-25 Sephadex followed by treatment with polystyrene beads (SM-2 beads, Bio-Rad, Richmond, CA) and sterile filtration gave conjugates that were free of unconjugated drug.
  • the BR64:ADR ratios ranged from 3.0-5.0.
  • the BR64-ADR conjugate was then tested for its
  • L6-ADR conjugate was used as a negative control.
  • the BR64-ADR conjugate did not display such killing on antigen-negative target cells (data not shown).
  • the BR64 antibody was tested for reactivity with a variety of immobilized purified glycolipids of known carbohydrate structures, using an ELISA assay in which the antigens and antibody were used in excess.
  • the glycolipids were dried from methanol in microtiter wells at 100 ng/well.
  • Purified antibody was assayed at a concentration of 10 ⁇ g/ml in 0.01 M Tris-HCl, pH 7.4, containing 1% bovine serum albumin. Absorbance values were calculated as the average of duplicate wells.
  • the subclass of the original BR64 antibody was switched from IgG1 to IgG2a.
  • Variants of the BR64 cell line (ATCC No. HB 9895) producing an altered heavy chain isotype were generated by a combination of sib selection and cloning in soft agarose. Microtiter plates were seeded with 1,000 cells/well of the parental BR64 cells and naturally-occurring subclass-switch variants were selected as described by G. Spira et al., supra.
  • the BR64 cells in the wells were allowed to grow to near confluence in Iscoves Medium (Grand Island Biological Co., Grand Island, NY) supplemented with 15% FCS and 2X glutamine.
  • the medium has been filtered through a non-triton containing Millex filter (Millipore Corp.,
  • the cells After 7 days growth in the wells, the cells had reached near confluence and the supernatants from the wells were removed and assayed via an ELISA for the presence of an IgG2a immunoglobulin (see Spira et al., supra at p. 309). Positive wells were identified and guantitated using an automatic ELISA reader. The cells from each of the positive wells were replated into multiple wells of microtiter plates and allowed to grow for 7 days. The ELISA assay was
  • Determination of the ADCC activity of the BR64.60 monoclonal antibody was performed as described by Hellstrom et al., Proc. Natl. Acad. Sci. (USA), 82, pp. 1499-1502 (1985). Briefly, a short-term 51Cr-release test that measures the release of Cr as described by Cerrotini et al., Adv. Immunol., 18, pp. 67-132 (1974) was used as evidence of tumor-cell lysis, i.e., cytotoxicity.
  • LSM Lymphocyte Separation Medium
  • Spontaneous release was defined as the counts per minute (cpm) released into the medium from target cells exposed to neither antibodies nor lymphocytes, and total release was defined as the number of counts released from target cells that were osmotically lysed at the end of the assay. Percent cytotoxicity was calculated as follows: experimental group release - spontaneous release ⁇ 100 total release - spontaneous release
  • Effector cells were characterized by assessing their sensitivity to incubation with anti-serum to the Leu-11b surface marker and guinea pig complement, using procedures described by Hellstrom et al., in Monoclonal Antibodies and Cancer Therapy, UCLA Symposia on Molecular and Cellular Biology, New Series, Reisfeld & Sell, (eds.), Liss, NY, 27, pp. 149-164 (1985). This was done to measure the expression of the Leu-11b marker, which characterizes natural killer (NK) cells and is expressed by lymphocytes mediating ADCC against human carcinoma cells in the presence of monoclonal antibody BR64.60.
  • NK natural killer
  • BR64.60 mediates ADCC activity at concentrations of from 0.1-10 ⁇ g/ml antibody. This ADCC activity is seen when BR64.60 is tested on antigen-positive cell lines such as the lung and ovarian carcinoma cell lines used. The NK effector cells alone gave a background cytotoxicity ranging between 11-22% depending upon the particular cell lines used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un nouveau anticorps monoclonal réagit avec des cellules de carcinomes humains. En particulier, l'anticorps décrit est un anticorps monoclonal qui réagit avec un antigène de la membrane cellulaire glycolipidique à la surface des carcinomes humains. L'anticorps présente une sélectivité élevée par rapport à des cellules de carcinomes, une faible réactivité par rapport à certaines cellules humaines normales et ne présente aucune réactivité détectable par rapport à d'autres types de tumeurs, tels que lymphomes, sarcomes ou mélanomes. En outre, l'anticorps décrit est capable de pénétrer dans les cellules de carcinome auxquelles il se lie et est par conséquent particulièrement utile pour des applications thérapeutiques, par exemple en tant qu'anticorps entrant dans la composition d'un médicament composé d'anticorps et de substances chimiques ou d'anticorps et de toxines.
PCT/US1989/005802 1988-12-22 1989-12-22 Nouveaux anticorps monoclonaux de carcinomes humains WO1990006772A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP90501917A JPH04502702A (ja) 1988-12-22 1989-12-22 ヒト癌に対する新規なモノクローナル抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US289,635 1981-08-03
US28963588A 1988-12-22 1988-12-22
US443,696 1989-11-29

Publications (1)

Publication Number Publication Date
WO1990006772A1 true WO1990006772A1 (fr) 1990-06-28

Family

ID=23112388

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/005802 WO1990006772A1 (fr) 1988-12-22 1989-12-22 Nouveaux anticorps monoclonaux de carcinomes humains

Country Status (1)

Country Link
WO (1) WO1990006772A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CANCER AND METASTASIS REVIEWS, 1987, Vol. 6, NEPOM, "Anti-Idiotypic Antibodies and the Induction of Specific Tumor Immunity", pages 489-502. *
CANCER RESEARCH, August 1986, HELLSTROM, "Monoclonal Mouse Antibodies Raised Against Human Lung Carcinoma1", pages 3917-3923. *
JOURNAL OF IMMUNOLOGICAL METHODS, 1984, SPIRA, "The Identification of Monoclonal Class Switch Variants by Sib Selection and an ELISA Assay", pages 307-315. *
PROC. NATL. ACAD. SCI. U.S.A., September 1986, HELLSTROM, "Antitumor Effects of L6, an IgG2a Antibody That Reacts with Most Human Carcinomas", pages 7059-7063. *
THE LANCET, 03 April 1982, SEARS, "Phase - I Clinical Trial of Monoclonal Antibody in Treatment of Gastrointestinal Tumors", pages 762-765. *

Similar Documents

Publication Publication Date Title
US5242824A (en) Monoclonal antibody to human carcinomas
CA2020247C (fr) Anticorps reagissants avec les carcinomes humains
AU629617B2 (en) Novel monoclonal antibody to novel antigen associated with human tumors
US5171665A (en) Monoclonal antibody to novel antigen associated with human tumors
US5411884A (en) Monoclonal antibody L53 which recognizes a human tumor-associated antigen
US5650291A (en) Monoclonal antibodies against an antigen associated with ovarian cervical and other tumors
AU617652B2 (en) Monoclonal paratopic molecule directed to human ganglioside gd2
WO1990006772A1 (fr) Nouveaux anticorps monoclonaux de carcinomes humains
PL167620B1 (pl) Sposób wytwarzania nowego mysiego przeciwciala monoklonalnego BR96 PL

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP